F. Bridoux, N. Leung, and C. Hutchison, Diagnosis of monoclonal gammopathy of renal significance, Kidney International, vol.87, issue.4, pp.698-711, 2015.
DOI : 10.1038/ki.2014.408

J. Fermand, F. Bridoux, and R. Kyle, How I treat monoclonal gammopathy of renal significance (MGRS), Blood, vol.122, issue.22, pp.3583-3590, 2013.
DOI : 10.1182/blood-2013-05-495929
URL : https://hal.archives-ouvertes.fr/hal-00945719

F. Fakhouri, V. Frémeauxfr´frémeaux-bacchi, N. , L. Cook, H. Pickering et al., C3 glomerulopathy: a new classification, Nature Reviews Nephrology, vol.118, issue.8, pp.494-499, 2010.
DOI : 10.1038/nrd3011

A. Servais, V. Frémeauxfr´frémeaux-bacchi, and M. Lequintrec, Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome, Journal of Medical Genetics, vol.44, issue.3, pp.193-199, 2007.
DOI : 10.1136/jmg.2006.045328
URL : http://europepmc.org/articles/pmc2598029?pdf=render

M. Pickering, D. Agati, V. Nester, and C. , C3 glomerulopathy: consensus report, Kidney International, vol.84, issue.6, pp.1079-1089, 2013.
DOI : 10.1038/ki.2013.377
URL : https://doi.org/10.1038/ki.2013.377

J. Hou, G. Markowitz, and A. Bomback, Toward a working definition of C3 glomerulopathy by immunofluorescence, Kidney International, vol.85, issue.2, pp.450-456, 2014.
DOI : 10.1038/ki.2013.340

A. Servais, L. Roumenina, and L. , Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies, Kidney International, vol.82, issue.4, pp.454-464, 2012.
DOI : 10.1038/ki.2012.63
URL : https://doi.org/10.1038/ki.2012.63

S. Sethi, F. Fervenza, and Y. Zhang, Proliferative Glomerulonephritis Secondary to Dysfunction of the Alternative Pathway of Complement, Clinical Journal of the American Society of Nephrology, vol.6, issue.5, pp.1009-1017, 2011.
DOI : 10.2215/CJN.07110810

G. Appel, H. Cook, and G. Hageman, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update, Journal of the American Society of Nephrology, vol.16, issue.5, pp.1392-1403, 2005.
DOI : 10.1681/ASN.2005010078
URL : http://jasn.asnjournals.org/content/16/5/1392.full.pdf

R. Smith, C. Harris, and M. Pickering, Dense deposit disease, Molecular Immunology, vol.48, issue.14, pp.1604-1610, 2011.
DOI : 10.1016/j.molimm.2011.04.005

S. Sethi, W. Sukov, and Y. Zhang, Dense Deposit Disease Associated With Monoclonal Gammopathy of Undetermined Significance, American Journal of Kidney Diseases, vol.56, issue.5, pp.977-982, 2010.
DOI : 10.1053/j.ajkd.2010.06.021
URL : http://europepmc.org/articles/pmc3970198?pdf=render

F. Bridoux, E. Desport, and V. Frémeauxfr´frémeaux-bacchi, Glomerulonephritis With Isolated C3 Deposits and Monoclonal Gammopathy: A Fortuitous Association?, Clinical Journal of the American Society of Nephrology, vol.6, issue.9, pp.2165-2174, 2011.
DOI : 10.2215/CJN.06180710
URL : https://hal.archives-ouvertes.fr/hal-00945701

L. Zand, A. Kattah, and F. Fervenza, C3 Glomerulonephritis Associated With Monoclonal Gammopathy: A Case Series, American Journal of Kidney Diseases, vol.62, issue.3, pp.506-514, 2013.
DOI : 10.1053/j.ajkd.2013.02.370
URL : http://europepmc.org/articles/pmc4435575?pdf=render

A. Levey, J. Bosch, J. Lewis, T. Greene, N. Rogers et al., A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation, Annals of Internal Medicine, vol.130, issue.6, pp.461-470, 1999.
DOI : 10.7326/0003-4819-130-6-199903160-00002

I. Myeloma and W. Group, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, Br J Haematol, vol.121, issue.5, pp.749-757, 2003.

J. Vardiman, J. Thiele, and D. Arber, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, vol.114, issue.5, pp.937-951, 2009.
DOI : 10.1182/blood-2009-03-209262

N. Leung, F. Bridoux, and C. Hutchison, Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant, Blood, vol.120, issue.22, pp.4292-4295, 2012.
DOI : 10.1182/blood-2012-07-445304
URL : https://hal.archives-ouvertes.fr/hal-00945713

J. Radhakrishnan and D. Cattran, The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines???application to the individual patient, Kidney International, vol.82, issue.8, pp.840-856, 2012.
DOI : 10.1038/ki.2012.280
URL : https://doi.org/10.1038/ki.2012.280

B. Durie, J. Harousseau, and J. Miguel, International uniform response criteria for multiple myeloma, Leukemia, vol.27, issue.9, pp.1467-1473, 2006.
DOI : 10.1038/sj.bmt.1703035
URL : http://www.nature.com/leu/journal/v20/n9/pdf/2404284a.pdf

G. Palladini, A. Dispenzieri, and M. Gertz, New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes, Journal of Clinical Oncology, vol.30, issue.36, pp.4541-4549, 2012.
DOI : 10.1200/JCO.2011.37.7614
URL : https://hal.archives-ouvertes.fr/hal-00945407

L. Roumenina, C. Loirat, M. Dragon-durey, L. Halbwachs-mecarelli, C. Sautes-fridman et al., Alternative complement pathway assessment in patients with atypical HUS, Journal of Immunological Methods, vol.365, issue.1-2, pp.8-26, 2011.
DOI : 10.1016/j.jim.2010.12.020

V. Frémeauxfr´frémeaux-bacchi, L. Weiss, P. Brun, and M. Kazatchkine, Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation, Nephrol Dial Transplant, vol.9, issue.7, pp.811-814, 1994.

A. Bomback, R. Smith, and G. Barile, Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis, Clinical Journal of the American Society of Nephrology, vol.7, issue.5, pp.748-756, 2012.
DOI : 10.2215/CJN.12901211
URL : http://cjasn.asnjournals.org/content/7/5/748.full.pdf

C. Nester and R. Smith, Treatment options for C3 glomerulopathy, Current Opinion in Nephrology and Hypertension, vol.22, issue.2, pp.231-237, 2013.
DOI : 10.1097/MNH.0b013e32835da24c
URL : http://europepmc.org/articles/pmc4437761?pdf=render

M. Vivarelli, A. Pasini, and F. Emma, Eculizumab for the Treatment of Dense-Deposit Disease, New England Journal of Medicine, vol.366, issue.12, pp.1163-1165, 2012.
DOI : 10.1056/NEJMc1111953
URL : http://www.nejm.org/doi/pdf/10.1056/NEJMc1111953

P. Giaime, L. Daniel, and S. Burtey, Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy, Clinical Nephrology, vol.83, issue.01, pp.57-60, 2015.
DOI : 10.5414/CN107945

C. Rabasco, T. Cavero, and E. Románrom´román, Effectiveness of mycophenolate mofetil in C3 glomerulonephritis, Kidney International, vol.88, issue.5, pp.1153-1160, 2015.
DOI : 10.1038/ki.2015.227

C. Blanc, S. Togarsimalemath, and S. Chauvet, Anti???Factor H Autoantibodies in C3 Glomerulopathies and in Atypical Hemolytic Uremic Syndrome: One Target, Two Diseases, The Journal of Immunology, vol.194, issue.11, pp.5129-5138, 2015.
DOI : 10.4049/jimmunol.1402770
URL : http://www.jimmunol.org/content/jimmunol/194/11/5129.full.pdf

T. Jokiranta, A. Solomon, M. Pangburn, P. Zipfel, and M. S. , Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H, J Immunol, vol.163, issue.8, pp.4590-4596, 1999.
DOI : 10.2210/pdb2loi/pdb

Y. Zhang, C. Nester, and B. Martin, Defining the Complement Biomarker Profile of C3 Glomerulopathy, Clinical Journal of the American Society of Nephrology, vol.9, issue.11, pp.1876-1882, 2014.
DOI : 10.2215/CJN.01820214
URL : http://cjasn.asnjournals.org/content/9/11/1876.full.pdf